5. Conclusions
Our predictive model could support modifying patients with de novo MBC who received IBR by classifying this population into different prognostic risk groups using a combination of clinicopathologic and treatment characteristics. Validation through various statistical methods proved the great performance of the model. Although future external validation with additional datasets is warranted, the developed nomogram holds promise as a valuable tool for guiding personalized treatment decisions in clinical practice.